Purpose: Selective retina therapy (SRT), the confined laser heating and destruction of retinal pigment epithelial cells, has been shown to treat acute types of central serous chorioretinopathy (CSC) successfully without damaging the photoreceptors and thus avoiding laser-induced scotoma. However, a benefit of laser treatment for chronic forms of CSC is questionable. In this study, the efficacy of SRT by means of the previously used 1.7-µs and shorter 300-ns pulse duration was evaluated for both types of CSC, also considering re-treatment for nonresponders. Material and Methods: In a two-center trial, 26 patients were treated with SRT for acute (n = 10) and chronic-recurrent CSC (n = 16). All patients presented with subretinal fluid (SRF) in OCT and leakage in fluorescein angiography (FA). SRT was performed using a prototype SRT laser system (frequency-doubled Q-switched Nd:YLF-laser, wavelength 527 nm) with adjustable pulse duration. The following irradiation settings were used: a train of 30 laser pulses with a repetition rate of 100 Hz and pulse durations of 300 ns and 1.7 µs, pulse energy 120-200 µJ, retinal spot size 200 µm. Because SRT lesions are invisible, FA was always performed 1 h after treatment to demonstrate laser outcome (5-8 single spots in the area of leakage). In cases where energy was too low, as indicated by missing FA leakage, energy was adjusted and the patient re-treated immediately. Observation intervals were after 4 weeks and 3 months. In case of nonimprovement of the disease after 3 months, re-treatment was considered. Results: Of 10 patients with active CSC that presents focal leakage in FA, 5 had completely resolved fluid after 4 weeks and all 10 after 3 months. Mean visual acuity increased from 76.6 ETDRS letters to 85.0 ETDRS letters 3 months after SRT. Chronic-recurrent CSC was characterized by less severe SRF at baseline in OCT and weaker leakage in FA than in acute types. Visual acuity changed from baseline 71.6 to 72.8 ETDRS letters after 3 months. At this time, SRF was absent in 3 out of 16 patients (19%), FA leakage had come to a complete stop in 6 out of 16 patients (38%). In 6 of the remaining chronic CSC patients, repeated SRT with higher pulse energy was considered because of persistent leakage activity. After the re-treatment, SRF resolved completely in 5 patients (83.3%) after only 25 days. Conclusion: SRT showed promising results in treating acute CSC, but was less effective in chronic cases. Interestingly, re-treatment resulted in enhanced fluid resolution and dry conditions after a considerably shorter time in most patients. Therefore, SRT including re-treatment if necessary might be a valuable CSC treatment alternative even in chronic-recurrent cases.

Wang M, Munch IC, Hasler PW: Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
Gass JD: Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63(suppl):1-139.
Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA: Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984;91:1554-1572.
Yannuzzi LA, Slakter JS, Gross NE, et al: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-298.
Hee MR, Puliafito CA, Wong C, et al: Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 1995;120:65-74.
Montero JA, Ruiz-Moreno JM: Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol 2005;89:562-564.
Loo RH, Scott IU, Flynn HW Jr: Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19-24.
Del Priore LV, Glaser BM, Quigley HA, Green R: Response of pig retinal pigment epithelium to laser photocoagulation in organ culture. Arch Ophthalmol 1989;107:119-122.
Wallow IH: Repair of the pigment epithelial barrier following photocoagulation. Arch Ophthalmol 1984;102:126-135.
Roider J, Michaud NA, Flotte TJ, Birngruber R: Response of the retinal pigment epithelium to selective photocoagulation. Arch Ophthalmol 1992;110:1786-1792.
Framme C, Kobuch K, Eckert E, Monzer J, Roider J: RPE in the perfusion culture and its response to laser application - preliminary report. Ophthalmologica 2002;216:320-328.
Roider J, Hillenkamp F, Flotte TJ, Birngruber R: Microphotocoagulation: selective effects of repetitive short laser pulses. Proc Natl Acad Sci USA 1993;90:8643-8647.
Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R: Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol 2000;84:40-47.
Brinkmann R, Hüttmann G, Rögener J, Roider J, Birngruber R, Lin CP: Origin of retinal pigment epithelium cell damage by pulsed laser irradiance in the nanosecond to microsecond time regimen. Lasers Surg Med 2000;27:451-464.
Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R: Comparison of cell damage thresholds in selective retina treatment (SRT) using 200 ns and 1.7 μs laser pulses in patients with various macular diseases. Lasers Surg Med 2008;40:616-624.
Framme C, Brinkmann R, Birngruber R, Roider J: Autofluorescence imaging after selective RPE laser treatment in macular diseases and clinical outcome: a pilot study. Br J Ophthalmol 2002;86:1099-1106.
Brinkmann R, Roider J, Birngruber R: Selective retina therapy (SRT) - a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006;302:51-69.
Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J: Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006;244:1638-1645.
Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J: Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 2011;95:83-88.
Ma J, Meng N, Xu X, Zhou F, Qu Y: Systemic review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 2014;92:594-601.
Framme C, Walter A, Gabler B, Roider J, Sachs HG, Gabel VP: Autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand 2005;83:161-167.
Kracht D, Brinkmann R: Green Q-switched microsecond laser pulses by overcoupled intracavity second harmonic generation. Optics Commun 2004;231:319-324.
Framme C, Schüle G, Roider J, Birngruber R, Brinkmann R: Influence of pulse duration and pulse number in selective RPE laser treatment. Lasers Surg Med 2004;34:206-215.
Schüle G, Elsner H, Framme C, Roider J, Birngruber R, Brinkmann R: Optoacoustic real-time dosimetry for selective retina treatment. J Biomed Opt 2005;10:064022.
Roider J, Wirbelauer C, Brinkmann R, Laqua H, Birngruber R: Control and detection of subthreshold effects in the first clinical trial of macular diseases. Invest Ophthalmol Vis Sci 1998;39:104.
Gabel VP, Birngruber R, Hillenkamp F: Visible and near infrared light absorption in pigment epithelium and choroid; in Shimizu K (ed): International Congress Series No. 450, XXIII Concilium Ophthalmologicum, Kyoto. Prince- ton, Excerpta Medica, 1978, pp 658-662.
Burumcek E, Mudun A, Karacorlu S, Arslan MO: Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997;104:616-622.
Khosla PK, Rana SS, Tewari HK, et al: Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers 1997;28:693-697.
Framme C, Walter A, Prahs P, Regler R, Theisen-Kunde D, Alt C, Brinkmann R: Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res 2009;34:568-579.
Baraki H, Feltgen N, Roider J, Hoerauf H, Klatt C: Central serous chorioretinopathy (CSC). Ophthalmologe 2010;107:479-492.
Maier M, Valet V, Feucht N, Lohmann CP: Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series. Ophthalmologe 2011;108:1027-1031.
Koss MJ, Beger I, Koch FH: Subtreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye 2012;26:307-314.
Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F: Mineralocorticoid receptor is involved in rat and human chorioretinopathy. J Clin Invest 2012;122:2672-2679.
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F: Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy. A pilot study. Retina 2013;33:2096-2102.
Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP: Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 2014;111:173-180.
Spitznas M: Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986;224:321-324.
Ruiz-Moreno JM, Lugo FL, Armada F, et al: Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2010;88:371-376.
Lim JI, Glassmann AR, Aiello LP, et al: Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2014;121:1073-1078.
Valet V, Lohmann CP, Maier M: Spectral domain OCT in central serous chorioretinopathy: description of retinal changes. Ophthalmologe 2012;109:879-887.
Neumann J, Brinkmann R: Self-limited growth of laser-induced vapor bubbles around single micro-absorbers. Appl Phys Lett 2008;93:033901.
Schuele G, Rumohr M, Huettmann G, Brinkmann R: RPE damage thresholds and mechanisms for laser exposure in the microsecond-to-millisecond time regimen. Invest Ophthalmol Vis Sci 2005;46:714-719.
Lee H, Alt C, Pitsillides CM, Lin CP: Optical detection of intracellular cavitation during selective laser targeting of the retinal pigment epithelium: dependence of cell death mechanism on pulse duration. J Biomed Opt 2007;12:064034.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.